SI1666463T1 - Kristal indolne spojine, ki vsebuje sulfonamid, in postopek za njegovo pripravo - Google Patents

Kristal indolne spojine, ki vsebuje sulfonamid, in postopek za njegovo pripravo

Info

Publication number
SI1666463T1
SI1666463T1 SI200431578T SI200431578T SI1666463T1 SI 1666463 T1 SI1666463 T1 SI 1666463T1 SI 200431578 T SI200431578 T SI 200431578T SI 200431578 T SI200431578 T SI 200431578T SI 1666463 T1 SI1666463 T1 SI 1666463T1
Authority
SI
Slovenia
Prior art keywords
sulfonamide
crystal
producing
same
indole compound
Prior art date
Application number
SI200431578T
Other languages
English (en)
Slovenian (sl)
Inventor
Keiko Takahashi
Kenji Hayashi
Taichi Abe
Takao Omae
Takashi Kato
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SI1666463T1 publication Critical patent/SI1666463T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
SI200431578T 2003-09-10 2004-09-01 Kristal indolne spojine, ki vsebuje sulfonamid, in postopek za njegovo pripravo SI1666463T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003318953 2003-09-10
PCT/JP2004/012649 WO2005026118A1 (ja) 2003-09-10 2004-09-01 スルホンアミド含有インドール化合物の結晶およびその製造方法
EP04772605A EP1666463B1 (en) 2003-09-10 2004-09-01 Crystal of sulfonamide-containing indole compound and process for producing the same

Publications (1)

Publication Number Publication Date
SI1666463T1 true SI1666463T1 (sl) 2011-02-28

Family

ID=34308544

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431578T SI1666463T1 (sl) 2003-09-10 2004-09-01 Kristal indolne spojine, ki vsebuje sulfonamid, in postopek za njegovo pripravo

Country Status (24)

Country Link
US (2) US7754894B2 (enExample)
EP (1) EP1666463B1 (enExample)
JP (1) JP4435090B2 (enExample)
KR (1) KR20060120644A (enExample)
CN (2) CN101165049A (enExample)
AT (1) ATE486849T1 (enExample)
AU (1) AU2004272400B2 (enExample)
BR (1) BRPI0414314A (enExample)
CA (1) CA2536995C (enExample)
CY (1) CY1110975T1 (enExample)
DE (1) DE602004029907D1 (enExample)
DK (1) DK1666463T3 (enExample)
ES (1) ES2354286T3 (enExample)
HR (1) HRP20100631T1 (enExample)
IL (2) IL174059A0 (enExample)
MX (1) MXPA06002732A (enExample)
NO (1) NO335256B1 (enExample)
NZ (1) NZ546111A (enExample)
PL (1) PL1666463T3 (enExample)
PT (1) PT1666463E (enExample)
RU (1) RU2336269C2 (enExample)
SI (1) SI1666463T1 (enExample)
TW (1) TW200514770A (enExample)
WO (1) WO2005026118A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3868534B2 (ja) * 1996-05-24 2007-01-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド誘導体の製造法および中間体
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
ES2341843T3 (es) * 2000-02-03 2010-06-29 EISAI R&D MANAGEMENT CO., LTD. Inhibidores de la expresion de integrina.
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Also Published As

Publication number Publication date
WO2005026118A1 (ja) 2005-03-24
CN100406440C (zh) 2008-07-30
DK1666463T3 (da) 2010-12-20
TWI349663B (enExample) 2011-10-01
CY1110975T1 (el) 2015-06-11
NO20061545L (no) 2006-06-09
EP1666463B1 (en) 2010-11-03
HRP20100631T1 (hr) 2010-12-31
CA2536995C (en) 2013-12-17
EP1666463A1 (en) 2006-06-07
TW200514770A (en) 2005-05-01
KR20060120644A (ko) 2006-11-27
AU2004272400A1 (en) 2005-03-24
ATE486849T1 (de) 2010-11-15
PL1666463T3 (pl) 2011-04-29
BRPI0414314A (pt) 2006-10-31
NO335256B1 (no) 2014-10-27
RU2006111454A (ru) 2006-08-27
JPWO2005026118A1 (ja) 2007-11-08
DE602004029907D1 (de) 2010-12-16
PT1666463E (pt) 2011-01-17
IL174059A0 (en) 2006-08-01
US7754894B2 (en) 2010-07-13
US20090247768A1 (en) 2009-10-01
AU2004272400B2 (en) 2010-03-04
US20070082941A1 (en) 2007-04-12
CN1849305A (zh) 2006-10-18
IL196569A0 (en) 2011-07-31
EP1666463A4 (en) 2007-12-12
HK1092796A1 (en) 2007-02-16
MXPA06002732A (es) 2006-06-05
CA2536995A1 (en) 2005-03-24
NZ546111A (en) 2008-11-28
JP4435090B2 (ja) 2010-03-17
CN101165049A (zh) 2008-04-23
ES2354286T3 (es) 2011-03-11
RU2336269C2 (ru) 2008-10-20

Similar Documents

Publication Publication Date Title
MY132094A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
GEP20104895B (en) Preparation of pregabalin and related compounds
IL166416A0 (en) Biaryl diazabicloalkane amides as nicotinic acetylcholine agonists
EE200200575A (et) Meetod perindopriili ja selle farmatseutiliselt sobivate soolade sünteesimiseks
PT1671949E (pt) Piridinilaminas substituídas
GEP20105036B (en) Perindopril
IL172512A0 (en) Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
AU2003261940A1 (en) Acicular silicon crystal and process for producing the same
SI1279665T1 (sl) Postopek za pripravo perindoprila, njegovih analogov in njegovih soli, z uporabo 2,5-diokso-oksazolidin-intermediatnih spojin
CY1107913T1 (el) Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc
MY138826A (en) 2,7-substituted indoles
ATE304014T1 (de) Neue kristalline form eines pyrrolidylthiocarbapenem-derivates
AU2003273219A1 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
MY136938A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
MY138698A (en) Method for synthesis of (2s)-indoline-2-carboxylic acid, and use in the synthesis of perindopril
GEP20084547B (en) Method for synthesis of perindopril and pharmaceutically acceptable salts thereof
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
PL1666463T3 (pl) Kryształ związku indolowego zawierającego sulfonamid i sposób jego wytwarzania
MY135359A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
MY136288A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
MY139348A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MY135169A (en) NEW PROCESS FOR THE SYNTHESIS OF (2S, 3aS, 7aS)-PERHYDROINDOLE-2-CARBOXYLIC ACID AND ESTERS THEREOF, AND APPLICATION IN THE SYNTHESIS OF PERINDOPRIL
AU2003242867A1 (en) Process for the synthesis of mosapride
PL379628A1 (pl) Nowy sposób syntezy perindoprilu i jego farmaceutycznie dopuszczalnych soli
MY136989A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof